Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Applicability of CCR Assessment Criteria in PMMR Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy Combined with Immunotherapy

NCT06794099 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT06794099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06794099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Applicability of CCR Assessment Criteria in PMMR Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy Combined with Immunotherapy
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Observational
Overall status
Completed
Start date
January 1, 2019
Completion date
January 1, 2025
Enrollment
177 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

complete response, immunotherapy, neoadjuvant chemoradiotherapy, pmmr/mss adenocarcinoma of the colon or rectum